Multimodal MRI characteristics of the glioblastoma infiltration beyond contrast enhancement.

abstract：:Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries (Pubmed, Scopus and Google Schol...

journal_title：Therapeutic advances in neurological disorders

authors： Angelini C,Pinzan E

更新日期：2019-05-06 00:00:00

abstract：:Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune condition affecting control of movement, mood, behaviour and potentially the heart...

journal_title：Therapeutic advances in neurological disorders

authors： Walker KG,Wilmshurst JM

更新日期：2010-09-01 00:00:00

abstract：Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

journal_title：Therapeutic advances in neurological disorders

authors： Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

更新日期：2019-12-02 00:00:00

abstract：:Blepharospasm is a focal (although usually bilateral) dystonia of the orbicularis oculi muscles, producing excessive eye closure. This produces significant disability through functional blindness. Botulinum neurotoxins (BoNT) have become the treatment of choice for blepharospasm; the impressive response rate and the t...

journal_title：Therapeutic advances in neurological disorders

authors： Hellman A,Torres-Russotto D

更新日期：2015-03-01 00:00:00

abstract：:The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

journal_title：Therapeutic advances in neurological disorders

authors： Peppin JF,Pappagallo M

更新日期：2014-01-01 00:00:00

abstract：Background:Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more robustly with clinical disability than traditional, lesion-based metrics. We compare Structural Image Evaluation using Normalisation of Atrophy (SIENA) with the icobrain longitudinal pipeline (icobrain long), for assessment of long...

journal_title：Therapeutic advances in neurological disorders

authors： Beadnall HN,Wang C,Van Hecke W,Ribbens A,Billiet T,Barnett MH

更新日期：2019-01-25 00:00:00

abstract：:The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

journal_title：Therapeutic advances in neurological disorders

authors： Fischer S,Weber W

更新日期：2017-11-22 00:00:00

abstract：Background:To investigate outcome and toxicity of high-dose systemic methotrexate (HDMTX)-based polychemotherapy and intracerebroventricular (ICV) chemotherapy via an Ommaya reservoir in elderly patients with primary central nervous system lymphoma (PCNSL). Methods:We performed a retrospective analysis on patients ⩾65...

journal_title：Therapeutic advances in neurological disorders

authors： Seidel S,Kowalski T,Margold M,Baraniskin A,Schroers R,Martus P,Schlegel U

更新日期：2020-10-07 00:00:00

abstract：:Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reacti...

journal_title：Therapeutic advances in neurological disorders

authors： Haussleiter IS,Brüne M,Juckel G

更新日期：2009-01-01 00:00:00

abstract：:Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset from clinical trials a...

journal_title：Therapeutic advances in neurological disorders

authors： Khatri BO

更新日期：2016-03-01 00:00:00

abstract：OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

journal_title：Therapeutic advances in neurological disorders

authors： Hadden RD,Marreno F

更新日期：2015-01-01 00:00:00

abstract：:The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

journal_title：Therapeutic advances in neurological disorders

authors： Tallner A,Pfeifer K,Mäurer M

更新日期：2016-07-01 00:00:00

abstract：:Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that preven...

journal_title：Therapeutic advances in neurological disorders

authors： Castro-Borrero W,Graves D,Frohman TC,Flores AB,Hardeman P,Logan D,Orchard M,Greenberg B,Frohman EM

更新日期：2012-07-01 00:00:00

abstract：Background:To compare the long-term clinical outcomes of different antihypertensive drugs in stable patients after acute hemorrhagic stroke (HS). Methods:From January 2001 to December 2013, patients with first-ever primary HS were identified in the National Health Insurance Research Database, Taiwan. Patients with tra...

journal_title：Therapeutic advances in neurological disorders

authors： Liu CH,Lin YS,Chi CC,Liou CW,Lee JD,Peng TI,Lee TH

更新日期：2018-09-28 00:00:00

abstract：Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

journal_title：Therapeutic advances in neurological disorders

authors： Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

更新日期：2020-08-10 00:00:00

abstract：Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

journal_title：Therapeutic advances in neurological disorders

authors： Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

更新日期：2019-04-24 00:00:00

abstract：:Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three choline...

journal_title：Therapeutic advances in neurological disorders

authors： Yiannopoulou KG,Papageorgiou SG

更新日期：2013-01-01 00:00:00

abstract：:For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms...

journal_title：Therapeutic advances in neurological disorders

authors： Awad A,Stüve O

更新日期：2009-11-01 00:00:00

abstract：:Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. However, the role of magnetic resonance imaging (MRI) in MS goes far beyond its clinical application. Indeed, advanced imaging techniques have helped to detect different components of MS patho...

journal_title：Therapeutic advances in neurological disorders

authors： Cortese R,Collorone S,Ciccarelli O,Toosy AT

更新日期：2019-06-27 00:00:00

abstract：:Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

journal_title：Therapeutic advances in neurological disorders

authors： Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

更新日期：2018-08-09 00:00:00

abstract：:Cluster headache (CH) is a short-lasting unilateral headache associated with ipsilateral craniofacial autonomic manifestations. A positron emission tomography (PET) study has shown that the posterior hypothalamus is activated during CH attacks, suggesting that hypothalamic hyperactivity plays a key role in CH pathophy...

journal_title：Therapeutic advances in neurological disorders

authors： Leone M,Franzini A,Cecchini AP,Broggi G,Bussone G

更新日期：2010-05-01 00:00:00

abstract：Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

journal_title：Therapeutic advances in neurological disorders

authors： Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

更新日期：2020-07-30 00:00:00

abstract：:Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

journal_title：Therapeutic advances in neurological disorders

authors： Haggiag S,Ruggieri S,Gasperini C

更新日期：2013-11-01 00:00:00

abstract：:Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-daily, oral immunomodulatory therapy, has demonstrated efficacy across...

journal_title：Therapeutic advances in neurological disorders

authors： Miller AE

更新日期：2017-12-01 00:00:00

abstract：:Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase II...

journal_title：Therapeutic advances in neurological disorders

authors： Albrecht P,Bjørnå IK,Brassat D,Farrell R,Feys P,Hobart J,Hupperts R,Linnebank M,Magdič J,Oreja-Guevara C,Pozzilli C,Salgado AV,Ziemssen T

更新日期：2018-10-05 00:00:00

abstract：:Essential tremor (ET) is the most common adult movement disorder. Traditionally considered as a benign disease, it can cause an important physical and psychosocial disability. Drug treatment for ET remains poor and often unsatisfactory. Current therapeutic strategies for ET are reviewed according to the level of disco...

journal_title：Therapeutic advances in neurological disorders

authors： Gironell A,Kulisevsky J

更新日期：2009-07-01 00:00:00

abstract：:The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays...

journal_title：Therapeutic advances in neurological disorders

authors： Sorensen PS

更新日期：2008-09-01 00:00:00

abstract：Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To p...

journal_title：Therapeutic advances in neurological disorders

authors： Gklinos P,Mitsikostas DD

更新日期：2020-04-28 00:00:00

abstract：:Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (...

journal_title：Therapeutic advances in neurological disorders

authors： Steinhoff BJ,Staack AM

更新日期：2019-09-09 00:00:00

abstract：:Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

journal_title：Therapeutic advances in neurological disorders

authors： Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

更新日期：2020-06-03 00:00:00